Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PALOMA-2: Subcutaneous amivantamab regimens in advanced or metastatic EGFR-mutated NSCLC
jRCT2051220116Phase 2Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Oct 2023
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of amivantamab in non-small cell lung cancer (NSCLC) (8 cohorts), sponsored by Janssen Pharmaceutical. Primary endpoints: Objective response rate based on investigator assessment, Number of participants with adverse events and 3 more. Started Oct 2023; status: recruiting.
02
Drugs
amivantamab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on jRCT2051220116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051220116.